PUBLIC COMPANY
save$IONSIONIS PHARMACEUTICALS INC
$IONS43.47+0.10%Carlsbad, CA, USupdated 20d ago
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.
community read0 votes
pipeline
7
marketed
2
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(7)
pipeline depth7 products
3Phase 21Phase 32Marketed1pre_registration
Marketed
donidalorsen sodium
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…
Marketedolezarsen sodium
Hypertriglyceridemia
Phase 3obudanersen sodium
Angelman Syndrome
Phase 2ION-283
Lafora Disease (Unverricht Disease)
Phase 2ION-356
Pelizaeus-Merzbacher Disease (PMD)
Phase 2vadernersen sodium
X Chromosome Disorders
pre_registrationzilganersen sodium
Alexander Disease
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earningsWhen Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.biospace · 3d ago
- Deep dive: Cardiovascular calamities and catalystsBioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.biospace · 4d ago
- PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicingMean splicing correction for PepGen’s PGN-EDODM1 was 46.5% at week 13, compared to under 30% for competitors like Dyne Therapeutics, Novartis and Ionis Pharmaceuticals.biospace · 5d ago
- PepGen's oligo succeeds in Phase 2; Ionis' and ImmunityBio's stocks sagPlus news about Coherus Oncology, JW Therapeutics and PsiThera. PepGen’s positive mid-stage results in DM1: PepGen said its oligonucleotide therapy PGN-EDODM1 showed positive early signals in a coh…endpoints · 6d ago
- STAT+: Ionis Pharmaceuticals shares plummet after slow rollout of biotech’s triglyceride-lowering drugIonis Pharmaceuticals lost more than $1 billion in market value on Monday after the company slashed sales projections for a triglyceride-lowering drug.stat · 7d ago
- Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivalsFull data from the Phase 3 HORIZON trial of Novartis' pelacarsen failed to show any apparent benefit, leading analysts to further reduce the odds of success for Lp(a)-lowering competitors such as A…biospace · 7d ago
- GSK vaccine sales miss expectations amid falling demand from adultsWith pressure on GSK’s vaccine business, analysts predict the U.K. pharma will face challenges as it prepares for the loss of exclusivity on a key product.biospace · 19d ago
- Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitionsRoche's Genentech has put numbers behind its phase 3 success in IgA nephropathy (IgAN), reporting that antisense oligonucleotide sefaxersen reduced a key marker of kidney damage by 43.1% compared w…fiercebiotech · 25d ago
- GSK, Ionis hepatitis B functional cure breaks open market for followersThe approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.biospace · 25d ago
- Why researchers may have found the biological culprit behind Angelman syndromeScientists have known for a while that Angelman syndrome is caused by the loss of a specific gene, but they didn't understand how this gene loss leads to the failure of brain development in infants…fiercebiotech · 26d ago
Data sources
last refreshed 51m ago
Found something off?
comments(0)
5-min edit window · permanent after that